Payment overview · 2025
General Payments
$1,686.11
89 reported records · 16 companies
Healthcare provider profile · identity verified
Cody Ronald Jackson, M.D.
Allopathic & Osteopathic Physicians|General Practice · SAN DIEGO, CA · NPI 1770715146
Verified facts
What the public records show
CMS Open Payments records show Cody Ronald Jackson, M.D. received $1,686.11 in general payments during 2025 across 89 reported records.
Gilead Sciences, Inc. accounted for 33.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Biktarvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $567.90 | 33.7% | 34 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $289.16 | 17.1% | 20 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $196.90 | 11.7% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $144.70 | 8.6% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $110.63 | 6.6% | 5 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $77.35 | 4.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.71 | 3.0% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $46.67 | 2.8% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $39.31 | 2.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.05 | 1.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $26.60 | 1.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.06 | 1.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.26 | 1.3% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $22.24 | 1.3% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $22.11 | 1.3% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $18.46 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,686.11 | 89 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $289.16 | 20 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $196.90 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $144.70 | 12 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $110.63 | 5 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $77.35 | 3 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $62.50 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $49.71 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $46.67 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $39.31 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.05 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $26.60 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.06 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.06 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $22.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | 15 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
104 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 210 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 157 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 154 | 51 |
| Gabapentin | Gabapentin | 119 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 109 | 34 |
| Ozempic | Semaglutide | 104 | 20 |
| Omeprazole | Omeprazole | 85 | 28 |
| Lisinopril | Lisinopril | 82 | 30 |
| Metformin Hcl | Metformin Hcl | 72 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 19 |
| Losartan Potassium | Losartan Potassium | 66 | 21 |
| Telmisartan | Telmisartan | 47 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 46 | 13 |
| Naproxen | Naproxen | 43 | 20 |
| Trazodone Hcl | Trazodone Hcl | 42 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 15 |
| Simvastatin | Simvastatin | 38 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 37 | 12 |
| Carvedilol | Carvedilol | 35 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | 25 |
| Eliquis | Apixaban | 32 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 32 | 13 |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 32 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 31 | 14 |
| Jardiance | Empagliflozin | 29 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | 13 |
| Indapamide | Indapamide | 28 | 13 |
| Mirtazapine | Mirtazapine | 28 | 15 |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 12 |
| Allopurinol | Allopurinol | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | 12 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | 11 |
| Alprazolam | Alprazolam | 21 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Furosemide | Furosemide | 19 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 19 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 18 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Prednisone | Prednisone | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,686.11 · 89 records | Gilead Sciences, Inc. | APRETUDE, APTIMA, Biktarvy, Cologuard Collection Kit, Extended Holter, INJECTAFER, JOURNAVX, MOUNJARO, QULIPTA, Saxenda, TZIELD, UBRELVY, Veozah, WaveWriter Alpha Prime 16, Wegovy, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error